Insights
Insights From Our Experts
Articles
Why Humans Must Be Part of the Bigger AI Picture
As AI reshapes how work gets done across industries, all organizations including life sciences are being challenged to balance speed, scale, and innovation with something equally critical: trust. Faruk Capan, Chief Innovation Officer at EVERSANA, explores…
You Cannot Commercialize What is Not Compliant
Most launch delays don’t start in the clinic—they stem from overlooked gaps in commercial compliance. Complete Response Letters (CRLs), though one of the greatest threats to launch success, are largely preventable with the proper commercial compliance…
EVERSANA Back as Global Host and Presenting Sponsor for Frontiers Health 2026
EVERSANA will return as Global Host and Presenting Sponsor of Frontiers Health 2026, taking place in Berlin on October 20–21. As one of the premier events for the global health innovation ecosystem, Frontiers Health brings together…
The Stability Advantage: Why Revenue Protection is the New Standard in Commercial Deployment
Is your commercial field force truly operating at full capacity? Even when a team boasts 100% headcount, the reality is that true productivity rarely matches that number. Organizations are quietly forfeiting revenue, not just to market competitors, but to the continuous…
The Indispensable Edge: Why the EVERSANA AI Agency Platform is a Must-Have for Expert Oncology Marketers
The oncology landscape is more complex, specialized, and competitive than ever before. To succeed in this data-driven world, expert oncology marketers need more than just traditional strategies— they need an intelligent approach to commercialization, launch readiness,…
U.S. Drug Pricing Is Entering a More Complex Phase
The U.S. drug pricing landscape is undergoing a fundamental transformation. Historically insulated from international reference pricing, new policy developments, such as the emergence of TrumpRx and Most Favored Nation (MFN) dynamics, are dismantling traditional benchmarks. Instead of relying on a single,…
Bridging Evidence Gaps in mCRPC: Highlighting the Potential of Talazoparib plus Enzalutamide
Innovation in oncology is accelerating, but the evidence needed to guide treatment decision-making often lags behind. This is particularly evident in metastatic castration-resistant prostate cancer (mCRPC). In mCRPC, multiple PARP inhibitors combined with androgen receptor pathway…
Decoding the Dialogue: Transforming MSL Interactions into Congress Intelligence
Oncology innovation is accelerating, but the ability to turn congress interactions into timely, actionable insights remains a challenge. High volumes of unstructured MSL and HCP data often slow analysis, limit visibility and delay strategic action. This…
The Shattered Glass: Why the Future of Oncology Patient Support is an Agentic Ecosystem, Not a Portal
Oncology innovation is accelerating, but the systems supporting it are falling behind – creating administrative friction, fragmented workflows, and delays in care. This challenge is the focus of our new thought leadership series, beginning with this…
Your Market Access Model is Bleeding Value
Your market access model may be quietly eroding more value than you realize. In today’s environment, up to 50% of commercial value is lost due to market access challenges. As policy pressures from the IRA, evolving…